This is, indeed, part of a wider trend of mutual support at the fringes of pharmacology, with similar user groups forming to monitor off-label use of peptide drugs and thus, in effect, running informal, uncontrolled trials. Whether those now taking GLP-1 RAs prophylactically will live to regret doing that or, conversely, will live long enough not to, remains to be seen.
